AI-based pathology diagnosis tool in development detects 7 types of gastric cancer

Evident, a wholly owned subsidiary of Olympus Corporation, announced the latest results from its ongoing joint research program to create an AI-based pathology diagnostic tool at the 20th annual meeting of the Japanese Society of Digital Pathology. The results show the diagnostic tool in development succeeded in expanding its AI detection to seven types of gastric cancer, highlighting its versatility for a range of pathology applications.

Meeting the demand for diagnostic tools

There is an increasing demand for diagnostic tools that can help reduce the workload of pathologists. To meet this need, Evident began a collaboration with the National Hospital Organization Kure Medical Center and Chugoku Cancer Center in 2017 to develop an AI-based pathology diagnosis tool.

The first testing phase showed the diagnostic tool could successfully identify adenocarcinoma tissue from pathology whole-slide images. As part of the second research phase that began in November 2020, the tool was tested on 2,717 pathology whole-slide images provided by six hospitals in Japan to improve its versatility and accuracy.

Results from the second research phase

By significantly increasing the amount of image data through collaboration with the hospitals, the diagnostic tool improved its AI detection of adenocarcinoma of tubular and poorly differentiated types and expanded its AI detection to identify other gastric cancers. It achieved a false negative rate of 0 to 2.5% in seven types of gastric cancer: adenocarcinoma, of tubular, papillary, mucinous and poorly differentiated types, gastrointestinal stromal tumor, MALT lymphoma, and diffuse large B-cell lymphoma. A common AI discrimination threshold* was set for all hospitals, demonstrating the improved versatility of the software.

As the second research phase continues, Evident aims to further refine the tool to prepare it for commercial use. The goal of this program is to deliver an AI pathology diagnosis software that can assist pathologists by 2023.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evident Corporation. (2022, September 13). AI-based pathology diagnosis tool in development detects 7 types of gastric cancer. News-Medical. Retrieved on December 02, 2022 from https://www.news-medical.net/news/20220913/AI-Based-pathology-diagnosis-tool-in-development-detects-7-types-of-gastric-cancer.aspx.

  • MLA

    Evident Corporation. "AI-based pathology diagnosis tool in development detects 7 types of gastric cancer". News-Medical. 02 December 2022. <https://www.news-medical.net/news/20220913/AI-Based-pathology-diagnosis-tool-in-development-detects-7-types-of-gastric-cancer.aspx>.

  • Chicago

    Evident Corporation. "AI-based pathology diagnosis tool in development detects 7 types of gastric cancer". News-Medical. https://www.news-medical.net/news/20220913/AI-Based-pathology-diagnosis-tool-in-development-detects-7-types-of-gastric-cancer.aspx. (accessed December 02, 2022).

  • Harvard

    Evident Corporation. 2022. AI-based pathology diagnosis tool in development detects 7 types of gastric cancer. News-Medical, viewed 02 December 2022, https://www.news-medical.net/news/20220913/AI-Based-pathology-diagnosis-tool-in-development-detects-7-types-of-gastric-cancer.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
The Art of Science: EVIDENT Launches Expanded Global Image of the Year Contest